CD8+ T cells represented in the ACT strategy are the milestone of cancer immunotherapy due to their ability to specifically recognize and kill tumor cells by the ligation of TCR with the tumor antigen peptide presented on the MHC. The gene discussed is CD8A; the disease is cancer.